The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Are BCL2 and MCL1 inhibitors the key against myeloma?
Enrique Ocio, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, highlights how targeting BCL2 and MCL1 provide an important thereapeutic strategy for multiple myeloma (MM). Dr Ocio discusses the overexpression of MCL1 in myeloma cells and its implications for treatment. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
